Page last updated: 2024-12-07
ksg 504
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
KSG 504: has superior selectivity and affinity to CCK-A receptors; derived from proglumide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 132011 |
MeSH ID | M0226329 |
Synonyms (10)
Synonym |
---|
l-arginine, mono((r)-5-((3-methoxypropyl)pentylamino)-4-((2-naphthalenylsulfonyl)methyl)-5-oxopentanoate) |
137005-17-5 |
ksg-504 |
ksg 504 |
4-n-(3-methoxypropyl)-n-pentylcarbamoyl-5-(2-naphthylsulfonyl)pentanoic acid |
AKOS030531694 |
DTXSID70929658 |
arginine--5-[(3-methoxypropyl)(pentyl)amino]-4-[(naphthalene-2-sulfonyl)methyl]-5-oxopentanoic acid (1/1) |
(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid;(4r)-5-[3-methoxypropyl(pentyl)amino]-4-(naphthalen-2-ylsulfonylmethyl)-5-oxopentanoic acid |
l-arginine, mono[(4r)-5-[(3-methoxypropyl)pentylamino]-4-[(2-naphthalenylsulfonyl)methyl]-5-oxopentanoate] (9ci) |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 12 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |